OR WAIT null SECS
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
February 03, 2021
Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.
Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.
February 02, 2021
Open communication and transparency coupled with technical expertise foster strong long-term manufacturing partnerships.
February 01, 2021
Best practices can help ensure supply chain flexibility and viability for biologic drugs in clinical trials.
January 29, 2021
Although a necessity, companies must strike a critical balance between protecting innovations with IP and providing affordable access to medicines.
January 15, 2021
The collaboration will focus on up to three types of lung and gastrointestinal cancers.
January 05, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 04, 2021
Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%.
January 03, 2021
The right partner can help companies overcome key formulation challenges for biologic drugs.